Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine
Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine
复制标题
DOI：
10.1177/0269881105056666
复制
发表时间：
2006-01-01
影响因子：
4.1
通讯作者：
Buis, C
中科院分区：
文献类型：
--
作者：
Baldwin, D;Bridgman, K;Buis, C
选择性去甲肾上腺素再摄取抑制剂瑞博西汀在性功能和性满意度方面可能优于选择性5-羟色胺再摄取抑制剂氟西汀和西酞普兰。通过检查来自英国中心的数据，比较瑞波西汀和帕罗西汀对DSM-IV重性抑郁症患者急性治疗的国际双盲、平行组、多中心随机对照试验中的性功能的影响。或帕罗西汀（20 mg马内），使用双模拟技术以保持盲态。第28天可增加剂量（瑞波西汀4 mg马内，6 mg阿托西汀;或帕罗西汀20 mg b.d.）。在所有研究访视时通过21项汉密尔顿抑郁量表（HAM-D）和严重程度临床总体印象量表（CGI-S）以及随机化后每次访视时的临床总体改善印象量表（CGI-I）评估抗抑郁疗效。在基线和第28天和第56天完成Rush性问卷的视觉模拟量表（VAS）项目来评估性功能和满意度。抑郁症状的严重程度逐渐降低（瑞波西汀，-14.3;帕罗西汀，-12.0：观察病例分析），两组之间无显著差异。有显著性差异（p < 0.05），在第4周和第8周评估性兴奋能力的VAS项目上，reboxvastatin具有优势，在第4周性想法频率方面，reboxvastatin具有非显著趋势优势（p = 0.05）和第8周（p = 0.08）;以及在第4周（p = 0.09）开始性活动的愿望。排除那些在参与本研究之前曾用任何药物治疗过性功能障碍的患者（n = 10），降低了研究结果的统计学意义，尽管reboxelastics.Sexual功能和满意度在reboxelastics. Sexual双盲急性治疗期间改善抑郁症患者的满意度，但reboxelastics. Sexual功能和满意度在reboxelastics. Sexual治疗期间改善更大，更快。
The selective noradrenaline re-uptake inhibitor reboxetine may have advantages over the selective serotonin re-uptake inhibitors fluoxetine and citalopram, in effects on sexual function and satisfaction. The effects of reboxetine and paroxetine on sexual function were compared by examining data from the UK centres in an international double-blind ftexible-dose parallel-group multi-centre randomized controlled trial of acute treatment of patients with DSM-IV major depression.Patients were randomly assigned to receive reboxetine (4 mg b.d.) or paroxetine (20 mg mane) using a double-dummy technique to preserve the blind. The dosage could be increased at day 28 (to reboxetine 4 mg mane, 6 mg nocte; or paroxetine 20 mg b.d.). Antidepressant efficacy was assessed by the 21-item Hamilton Rating Scale for Depression (HAM-D) and Clinical Global Impression Scale for Severity (CGI-S) at all study visits, and the Clinical Global Impression of Improvement (CGI-I) at each visit after randomization. Sexual function and satisfaction was assessed by visual analogue scale (VAS) items of the Rush Sexual Inventory completed at baseline and days 28 and 56.There were no significant differences between groups in demographic or clinical features at baseline. There was a gradual reduction in severity of depressive symptoms (reboxetine, -14.3; paroxetine, -12.0: observed case analysis), with no significant differences between groups. There were significant differences (p < 0.05), with advantages for reboxetine, at Week 4 and Week 8 on the VAS item assessing ability to become sexually excited, and non-significant trends with advantages for reboxetine, in frequency of sexual thoughts at Week 4 (p = 0.05) and Week 8 (p = 0.08); and in desire to initiate sexual activity at Week 4 (p = 0.09). Exclusion of patients who had ever experienced sexual dysfunction with any medication prior to participation in this study (n = 10) reduced the statistical significance of the findings, although there were still numerical advantages for reboxetine.Sexual function and satisfaction in depressed patients improves during double-blind acute treatment with reboxetine or paroxetine, but this improvement is greater and more rapid with reboxetine.